The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 1986-1992

  Aapro, M ^a   Molassiotis, A ^b   Dicato, M ^c   Pelaez I ^d   Rodriguez Lescure A ^e   Pastorelli, D ^f   Ma, L ^g   Burke, T ^g   Gu, A ^g   Gascon, P ^h   Roila, F ⁱ  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Hematology Oncology Luxembourg Medical Center   (Luxembourg)

^d HOSPITAL DE CABUEÑES   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^f Oncologic Institute of the Veneto   (Italy)

^g MERCK RESEARCH LABORATORIES   (United States)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ S MARIA HOSPITAL   (Italy)

Author keywords

Antiemetic therapy; Chemotherapy; Emesis; Guidelines; Nausea

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; IRINOTECAN; NAVELBINE; NEUROKININ 1 RECEPTOR ANTAGONIST; OXALIPLATIN; PALONOSETRON; SEROTONIN 3 ANTAGONIST; TEMOZOLOMIDE;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; VOMITING;

EID: 84864956209     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds021     Document Type: Article

References (26)

1. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21Suppl 5: v232-v243.
2. National Comprehensive Cancer Network (NCCN). Antiemesis. NCCN Guidelines 2011; Version 3 2011; http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf (12 October 2011, date last accessed).
3. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: american Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-4198.
4. Fabi A, Barduagni M, Lauro S et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 2003; 11: 156-161.
5. Mertens WC, Higby DJ, Brown D et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 2003; 21: 1373-1378.
6. Grunberg SM. Obstacles to the implementation of antiemetic guidelines. J Natl Compr Canc Netw 2009; 7: 601-605.
7. Kaiser R. Antiemetic guidelines: are they being used?. Lancet Oncol 2005; 6: 622-625.
8. Burmeister H, Aebi S, Studer C et al. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 2011 January 14, [epub ahead of print], doi:10.1007/s00520-010-1079-3.
9. Bloechl-Daum B, Deuson RR, Mavros P et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24: 4472-4478.
10. Cohen L, de Moor CA, Eisenberg P et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007; 15: 497-503.
11. Glaus A, Knipping C, Morant R et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004; 12: 708-715.
12. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 2011; 19: 131-140.
13. Ihbe-Heffinger A, Ehlken B, Bernard R et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004; 15: 526-536.
14. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-2494.
15. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011; 22: 30-38.
16. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5: 32-43.
17. Warr DG, Grunberg SM, Gralla RJ et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005; 41: 1278-1285.
18. Roila F. Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 2004; 12: 446-453.
19. Nolte MJ, Berkery R, Pizzo B et al. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 1998; 16: 771-778.
20. Dranitsaris G, Leung P, Warr D. Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 2001; 9: 611-618.
21. Multinational Association of Supportive Care in Cancer (MASCC). MASCC/ESMO Antiemetic Guidelines 2011. http://www.mascc.org/mc/page.do?sitePageId=88041 [12 October 2011, date last accessed].
22. Roila F, Hesketh PJ, Herrstedt JAntiemetic Subcommittee of the Multinational Association of Supportive Care in CancerPrevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
23. Molassiotis A, Saunders MP, Valle J et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008; 16: 201-208.
24. Booth CM, Clemons M, Dranitsaris G et al. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 2007; 5: 374-380.
25. Grunberg SM, Deuson RR, Mavros P et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100: 2261-2268.
26. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000; 20: 113-121.